LIFEライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:35):

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States...

Stats
本日の出来高	129 060
平均出来高	559 835
時価総額	109.71M
EPS	$0 ( 2024-03-14 )
次の収益日	( $-0.240 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.720
ATR14	$0.00500 (0.31%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-05	Shukla Sanjay	Buy	10 375	Common stock
2024-02-05	Shukla Sanjay	Sell	10 375	Restricted Stock Unit
2024-02-05	Broadfoot Jill Marie	Buy	3 750	Common stock
2024-02-06	Broadfoot Jill Marie	Sell	1 590	Common stock
2024-02-05	Broadfoot Jill Marie	Sell	3 750	Restricted Stock Unit

INSIDER POWER
92.95
Last 99 transactions
Buy: 4 079 228 \| Sell: 350 127

ボリューム相関

長: 0.41 (neutral)

短: 0.35 (neutral)

Signal:(63.065) Neutral

aTyr Pharma Inc 相関

10 最も正の相関

10 最も負の相関
TYHT	-0.821

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

aTyr Pharma Inc 相関 - 通貨/商品

0.08
( neutral )

-0.03
( neutral )

0.00
( neutral )

0.67
( moderate )

0.02
( neutral )

aTyr Pharma Inc 財務諸表

Annual	2023
収益:	$353 000
総利益:	$-2.39M (-676.49 %)
EPS:	$-0.940

FY	2023
収益:	$353 000
総利益:	$-2.39M (-676.49 %)
EPS:	$-0.940

FY	2022
収益:	$10.39M
総利益:	$8.69M (83.68 %)
EPS:	$-1.560

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.770

Financial Reports:

No articles found.

aTyr Pharma Inc

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.